GB2268931A — Azabicyclic tachykinin-receptor antagonists
Assigned to Organon Pharma UK Ltd · Expires 1994-01-26 · 32y expired
What this patent protects
Compounds of formula (I), and salts and prodrugs thereof: <IMAGE> wherein Q is the residue of an optionally substituted azabicyclic @ ring system (preferably quinuclidine); X represents O, S, CH2 or CH; Y represents H, OH, =O or halo; R<1> represents phenyl option…
USPTO Abstract
Compounds of formula (I), and salts and prodrugs thereof: <IMAGE> wherein Q is the residue of an optionally substituted azabicyclic @ ring system (preferably quinuclidine); X represents O, S, CH2 or CH; Y represents H, OH, =O or halo; R<1> represents phenyl optionally substituted by halo @ or trifluoromethyl; and R<3>, R<4> and R<5> independently represent @ H, C1-6 alkyl, c2-6 alkenyl, C2-6 @ alkynyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, @ -OR<a>, SCH3, SOCH3, @ SO2CH3, NR<a>R<b>, @ -NR<a>COR<b>, -NR<a>CO2R<b>, @ -CO2R<a> or -CONR<a>R<b> (where R<a> and R<b> independently represent H, @ C1-6 alkyl, phenyl or trifluoromethyl); with the proviso that when X is O or S, Y is H; @ are tachykinin receptor antagonists useful in therapy.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.